Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
69.50    1.00 (1.46%)
Bid:
68.00
Ask:
71.00
Spread: 3.00 (4.412%)
Market Cap: £316.30m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Re Agreement

7 Jan 2008 10:50

Avacta Group plc

Strategic Alliance

Broader service offering augments market position

Avacta Group plc ("Avacta"), which provides novel detection and analysis technology for the pharmaceutical, defence & security and clinical diagnostics markets, announces an agreement with Agenda 1 Analytical Services Ltd ("Agenda 1").

Agenda 1 provides a wide range of analytical techniques and services from bespoke laboratories located close to Avacta in Bradford, UK. Agenda 1 provides a complementary service offering to Avacta by focusing on small molecule therapeutics, whereas Avacta's strength is in the provision of expert analysis to companies developing large molecule biopharmaceuticals. Consequently, the agreement provides an immediate synergy allowing Avacta to offer an enhanced analytical service to a much wider base of pharmaceutical companies along with access to expertise, resources and technology not available in-house.

The Directors of Avacta believe that this enhanced product offering will enable accelerated growth of the analytical services business because it affords Avacta the ability to offer a greater range of the services required by the pharmaceutical industry. There will be no consideration payable by Avacta for this sharing of services.

Professor Alastair Smith, Chief Executive Officer, Commented:

"Avacta Analytical Limited, Avacta's technical services subsidiary, has made very good progress in its provision of analytical services to the biopharmaceutical sector but we are aware that some potential clients require an even broader range of services than we have been able to offer to date. Today's agreement allows us to extend our services and cover a greater range of the pharmaceutical industry's requirements and my expectation is that this will lead to more rapid growth in the services business of the Group."

7 January 2008Enquiries:Avacta Group plc Tel: 0870 835 4367 Russell Hodgetts Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk WH Ireland Ltd (Nominated Adviser) Tel: 0161 832 2174 David Youngman/Robin Gwyn BankOra Ltd Tel: 020 7562 4700 Michael Brennan/Henry Turcan Notes to Editors:About Avacta

Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address needs in the pharmaceutical, defence and clinical diagnostics markets. Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High value solutions in defence and clinical diagnostics are also being provided by Avacta's development programmes.

A successful and growing part of the Avacta business model is its technical services arm, Avacta Analytical Ltd which is focused on providing leading edge contract research to the biopharmaceutical and healthcare/personal-care materials sectors. Avacta listed on AIM in August 2006 through the reverse takeover of Readybuy plc which changed its name to Avacta Group plc.

About Agenda 1

Agenda 1 grew from the analytical laboratories of Nektar Therapeutics (UK) Ltd - (a.k.a. Bradford Particle Design Ltd). The team was formed to utilise their experience as a development group supporting both new technologies and new pharmaceutical products working from early stage project initiation up to and including enabling the release of material for clinical trials.

Agenda 1's client base ranges from major pharmaceutical companies through to virtual companies, and emerging and growing Bio-Pharma businesses. Agenda 1 has developed a number of flexible approaches to help clients access their lab facilities. These include the option to place contract staff into the laboratories via a unique structure with Synergy Outsourcing, a company specialising in scientific personnel. Agenda 1 has also recently launched an innovative "Lab Time-Share" approach, which saw the company awarded the prestigious Royal Society of Chemistry "SME of the month" award for July 2007.

AVACTA GROUP PLC
Date   Source Headline
18th Apr 20117:00 amRNSInterim Results
12th Apr 201112:42 pmRNSIssue of Equity
29th Mar 20117:00 amRNSExclusive distribution agreement with DKSH Japan
28th Mar 20117:00 amRNSAdditional Listing
22nd Mar 201110:11 amRNSAdditional Listing
17th Mar 20117:00 amRNSDirectorate Change
4th Mar 20117:00 amRNSTrading Statement
23rd Feb 20117:00 amRNSRe Agreement
3rd Feb 20117:00 amRNSRe Agreement
3rd Feb 20117:00 amRNSIssue of Equity
27th Jan 20114:55 pmRNSHolding(s) in Company
27th Jan 20117:00 amRNSDirector/PDMR Shareholding
26th Jan 20117:00 amRNSIssue of Equity
25th Jan 201111:57 amRNSHolding(s) in Company
21st Jan 20113:47 pmRNSAGM Result and Placing
12th Jan 20117:00 amPRNPlacing, Issue of Equity and related party transaction
5th Jan 201111:59 amPRNExercise of Warrants
4th Jan 20116:28 pmPRNHolding(s) in Company
4th Jan 20117:00 amRNSProduct Sale
31st Dec 20109:57 amPRNHolding(s) in Company
30th Dec 20102:36 pmPRNHolding(s) in Company
25th Nov 20107:00 amRNSProduct Launch
15th Nov 20107:00 amPRNGrant of Options to Directors
3rd Nov 20107:00 amRNSFinal Results
27th Oct 20107:00 amRNSProduct Sale
27th Oct 20107:00 amRNSProduct Sale
26th Oct 20107:00 amPRNIssue of Equity
14th Oct 20107:00 amRNSRe Agreement
20th Sep 20107:00 amPRNLicensing Agreement
7th Sep 20105:08 pmPRNHolding(s) in Company
6th Sep 20107:00 amPRNDistribution Agreement
6th Aug 20109:55 amPRNDirector/PDMR Shareholding
29th Jul 20107:00 amPRNIssue of Equity
6th Jul 20107:00 amPRNIssue of Equity
1st Jun 20107:00 amPRNChange of Adviser
30th Apr 20107:00 amPRNHalf-yearly Report
8th Mar 20107:00 amRNSNotice of Results and Trading Update
3rd Mar 20107:00 amRNSAcquisition
22nd Feb 20102:42 pmRNSDirector/PDMR Shareholding
25th Jan 20107:00 amRNSResult of AGM
21st Dec 200910:35 amRNSIssue of Equity
26th Nov 20097:03 amRNSPreliminary Results
26th Nov 20097:00 amRNSIssue of Equity
4th Nov 20097:00 amPRNNotice of Results
21st Oct 20097:00 amPRNPlacing and Issue of Equity
6th Oct 20097:00 amRNSOptim - Second Order
28th Sep 20097:00 amPRNRe Agreement
16th Sep 20093:03 pmRNSHolding(s) in Company
11th Sep 20094:26 pmRNSHolding(s) in Company
11th Sep 20093:59 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.